Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2020

View Archived Issues

Angiopoietin trouble can lead to lymphedema

Prelude Therapeutics initiates phase I study of PRT-1419

Enrollment initiates in first-in-human study of ONC-206

New company Cullinan Florentine to develop bispecific antibody CLN-049 for AML

Phase I data for coadministered hookworm vaccine candidates, Na-GST-1 and Na-APR-1

PZ-1818, a dual-acting 5-HT6 receptor inverse agonist/MAO-B inhibitor

Arrowhead presents interim phase II data for ARO-AAT in AATD-associated liver disease

Interim results from ongoing phase Ib/II study of cavrotolimod

AstraZeneca discloses KRAS mutant inhibitors

Chaluesheng Medical Technology divulges RET inhibitors

Chinese researchers present exportin-1 receptor antagonists

New target identified for ZIKV-induced microcephaly

Ferro Therapeutics patents new GPX4 inhibitors

University of California discovers 5-HT2A receptor modulators

First patient dosed in phase II study of GC-4419 for COVID-19

New rat model of cortical demyelination reveals benefit of anti-CD20 antibody therapy

Enrollment ongoing in phase I study of INV-101

TFF reports topline safety data from phase I study of voriconazole inhalation powder

DoD grant to support Histogen's evaluation of HST-003 for regeneration of knee cartilage

INmune receives grant to support phase II testing of XPro-1595 in treatment-resistant depression

PARP1 inhibitor AG-014699 confers neuroprotection in experimental PD

AVM receives FDA clearance to study AVM-0703 for COVID-19- and influenza-related ARDS

Tiziana set to study nasally administered foralumab for treatment of COVID-19

Immune-Onc begins first-in-human study of IO-202 for AML and CMML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...